Brussels, Belgium-based UCB entered into a global licensing deal with Roche and Genentech to develop and commercialize UCB0107 in Alzheimer’s disease.
If you are not happy with the results below please do another search
50 search results for:
Bristol Myers Squibb and bluebird bio announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration for idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.
A brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus.
Three months after joining forces to develop an adjuvanted vaccine for Covid-19, Sanofi and GlaxoSmithKline reached an agreement with the U.K. government to provide up to 60 million doses of the preventative medication.
Geeta Vemuri is a trailblazer. Following her time as a Managing Partner at Baxter Ventures and Baxalta Ventures, Vemuri founded Agent Capital, a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.
Thrive Earlier Detection, headquartered in Cambridge, Massachusetts, closed on a Series B financing worth $257 million.
U.S. deaths from the novel coronavirus surpassed 150,000, a number higher than in any other country and nearly a quarter of the world’s total, according to a Reuters tally.
Digital-first creative agency Code and Theory has established Code and Theory Health – a new business unit dedicated to servicing brands and organizations within the healthcare industry – and added Scout Health, a 100-person agency focused on rare diseases, orphan drugs and specialty pharmaceuticals.
Moderna Inc. plans to price the company’s experimental coronavirus vaccine in a way that ensures broad access, and does not intend to conduct late-stage trials of the vaccine outside the United States.
Vineti and EVERSANA announced a partnership to improve access, affordability and patient support challenges in regenerative medicine.